Characterisation of micro-environmental and molecular changes in prostate tumour treated with bicalutamide
Androgen ablation therapy using bicalutamide (BCA) is a first line treatment for advanced localised prostate cancer; patients treated with this drug have an improved quality of life over 1- 2 years, however they frequently develop treatment resistant, metastatic tumours. Evidence from our laboratory...
| Main Author: | |
|---|---|
| Published: |
University of Ulster
2010
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.553874 |